
Albireo Pharma ALBO
Quartalsbericht 2022-Q3
hinzugefügt 08.11.2022
Albireo Pharma EV 2011-2026 | ALBO
EV Jährlich Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 417 M | 553 M | 211 M | 183 M | 232 M | 12.2 M | 11.9 M | 10.8 M | 8.4 M | 1.76 M | -8.73 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 553 M | -8.73 M | 148 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 21.77 | 1.68 % | $ 1.02 B | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
9.45 M | $ 0.92 | 3.05 % | $ 6.76 M | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
3.33 B | $ 22.44 | 2.16 % | $ 3.72 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Esperion Therapeutics
ESPR
|
1.16 B | $ 2.02 | 5.76 % | $ 420 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | ||
|
Galectin Therapeutics
GALT
|
306 M | $ 2.42 | 3.65 % | $ 155 M | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Heron Therapeutics
HRTX
|
411 M | $ 1.26 | 6.3 % | $ 210 M | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
ImmuCell Corporation
ICCC
|
69.7 M | $ 8.28 | -0.84 % | $ 74.7 M | ||
|
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | ||
|
InflaRx N.V.
IFRX
|
-2.36 M | $ 1.53 | 3.38 % | $ 152 M | ||
|
Aridis Pharmaceuticals
ARDS
|
38.2 M | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
-4.91 B | $ 103.31 | -2.04 % | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
-1.76 M | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
540 M | $ 4.14 | 1.47 % | $ 443 M | ||
|
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 23.57 | 1.33 % | $ 3 B | ||
|
Innate Pharma S.A.
IPHA
|
259 M | $ 1.39 | 0.72 % | $ 235 M | ||
|
Inventiva S.A.
IVA
|
129 M | $ 5.18 | 0.49 % | $ 138 M | ||
|
Jaguar Health
JAGX
|
57 M | $ 0.36 | -8.39 % | $ 840 K | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.46 | 1.04 % | $ 389 M | ||
|
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | ||
|
KalVista Pharmaceuticals
KALV
|
944 M | $ 20.08 | 2.29 % | $ 1.08 B | ||
|
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 2.99 | 2.05 % | $ 4.92 M | ||
|
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | ||
|
Kazia Therapeutics Limited
KZIA
|
141 M | $ 12.42 | 1.26 % | $ 1.65 B | ||
|
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B |